Sam Pallerla

This paper describes the scalable production of a de novo SARS-CoV-2 antiviral miniprotein in E. coli, achieving high purity and yield for preclinical and clinical use.

This paper describes the development and cGMP manufacturing of an HIV vaccine candidate for clinical trials, demonstrating scalable production and quality control.

This study evaluates the dose-dependent effects of the SMNP adjuvant on HIV Env-specific immune responses in non-human primates, showing increased memory T and B cell responses and neutralizing antibodies at higher doses.